<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04504344</url>
  </required_header>
  <id_info>
    <org_study_id>NC NM4R Pilot Project Program</org_study_id>
    <nct_id>NCT04504344</nct_id>
  </id_info>
  <brief_title>Non-invasive Brain Stimulation to Improve Quadriceps Muscle Function After Anterior Cruciate Ligament Reconstruction</brief_title>
  <official_title>Non-invasive Brain Stimulation to Improve Quadriceps Muscle Function After Anterior Cruciate Ligament Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcadia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcadia University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Quadriceps muscle dysfunction persists for years after anterior cruciate ligament&#xD;
      reconstruction (ACLR) and is related to poor self-reported outcomes, altered movement&#xD;
      patterns and joint loading associated with post-traumatic knee osteoarthritis (OA), and&#xD;
      higher risk of reinjury. Emerging evidence indicates that central drive (pathway from the&#xD;
      brain to the muscle of interest, i.e corticospinal excitability) to the quadriceps muscle is&#xD;
      reduced as early as 2 weeks after surgery and can persist for years after ACLR, meaning that&#xD;
      current rehabilitation strategies may not be addressing potential maladaptive changes in&#xD;
      central drive. Anodal tDCS is a neurostimulation technology that increases brain excitability&#xD;
      (i.e. central drive) and has the potential to address alterations in central drive and&#xD;
      quadriceps muscle performance. The purpose of this study is twofold: 1) to determine the&#xD;
      effects of anodal tDCS on central drive and quadriceps muscle performance in patients after&#xD;
      ACLR, and 2) determine the relationship between central drive and quadriceps muscle&#xD;
      performance in patients after ACLR. Central drive will be defined by two measures: 1) active&#xD;
      motor thresholds, and 2) slope of a stimulus response curve. Quadriceps muscle performance&#xD;
      will be defined by two measures: 1) isometric quadriceps strength, and 2) rate of torque&#xD;
      development (RTD). For purpose 1 the investigators hypothesize that measures of central drive&#xD;
      and quadriceps muscle performance will increase with administration of active anodal tDCS&#xD;
      compared to no change with sham tDCS. For purpose 2 the investigators hypothesize that both&#xD;
      measures of central drive will be associated with both measures of quadriceps performance,&#xD;
      with a stronger association between central drive and RTD. Following a cross-over design&#xD;
      patients 3-6 months from ACLR will receive active and sham anodal tDCS at different sessions&#xD;
      separated by 7-10 days while they ride a stationary bike for 20 minutes. Bike position and&#xD;
      intensity will be standardized for all patients to maximize quadriceps activity. Findings&#xD;
      from this study will expand our basic science knowledge on how tDCS effects different aspects&#xD;
      of corticospinal excitability and quadriceps strength, and lead to subsequent studies to&#xD;
      determine the effects of multiple sessions of tDCS on corticospinal excitability and&#xD;
      quadriceps muscle performance in patients recovering from ACLR.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>isometric quadriceps torque</measure>
    <time_frame>3-6 months after ACL Reconstruction</time_frame>
    <description>Nm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>quadriceps rate of torque development</measure>
    <time_frame>3-6 months after ACL Reconstruction</time_frame>
    <description>Nm/s</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corticospinal excitability - active motor threshold</measure>
    <time_frame>3-6 months after ACL Reconstruction</time_frame>
    <description>percent maximal stimulator output</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corticospinal excitability - slope of the stimulus response curve</measure>
    <time_frame>3-6 months after ACL Reconstruction</time_frame>
    <description>motor evoked potential/percent active motor threshold</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Anterior Cruciate Ligament Reconstruction</condition>
  <condition>Quadriceps Muscle Weakness</condition>
  <condition>Transcranial Direct Current Stimulation</condition>
  <arm_group>
    <arm_group_label>Active tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active tDCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham tDCS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Anodal transcranial direct current stimulation (tDCS) - Soterix Medical Inc, 1x1 tDCS (conventional)</intervention_name>
    <description>We will compare the effects of active versus sham tDCS on quadriceps strength and corticospinal excitability in patients recovering from ACLR.</description>
    <arm_group_label>Active tDCS</arm_group_label>
    <arm_group_label>Sham tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -Underwent primary ACL reconstruction within 3-6 months&#xD;
&#xD;
        Exclusion Criteria include:&#xD;
&#xD;
          -  multiple ligament reconstruction&#xD;
&#xD;
          -  osteo-chondral procedures&#xD;
&#xD;
          -  any previous lower extremity surgery&#xD;
&#xD;
          -  previous ACL injury&#xD;
&#xD;
          -  Metal or implants in the head or neck&#xD;
&#xD;
          -  history of neurological disease, seizures, severe migraines, and concussion within the&#xD;
             last 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ryan Zarzycki, PT, PhD</last_name>
    <phone>2155728527</phone>
    <email>zarzyckir@arcadia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ryan Zarzycki</name>
      <address>
        <city>Glenside</city>
        <state>Pennsylvania</state>
        <zip>19038</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Zarzycki, PT, PhD</last_name>
      <phone>215-572-8527</phone>
      <email>zarzyckir@arcadia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2020</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Arcadia University</investigator_affiliation>
    <investigator_full_name>Ryan Zarzycki</investigator_full_name>
    <investigator_title>Assistant Professor Department of Physical Therapy</investigator_title>
  </responsible_party>
  <keyword>corticospinal excitability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Weakness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 28, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT04504344/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 28, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT04504344/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

